Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.1667.

A number of equities analysts recently commented on the company. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Weiss Ratings upgraded shares of Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Lifesci Capital lowered shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, Maxim Group cut their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors have recently bought and sold shares of CNTX. Two Sigma Securities LLC lifted its position in shares of Context Therapeutics by 388.7% in the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after buying an additional 48,871 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Context Therapeutics during the 2nd quarter worth about $30,000. ADAR1 Capital Management LLC acquired a new position in shares of Context Therapeutics during the 2nd quarter valued at about $416,000. Clear Harbor Asset Management LLC acquired a new position in shares of Context Therapeutics during the 2nd quarter valued at about $51,000. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Context Therapeutics in the 2nd quarter valued at approximately $1,625,000. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Price Performance

Shares of CNTX stock opened at $0.47 on Tuesday. Context Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $3.62. The stock’s 50-day moving average is $0.59 and its two-hundred day moving average is $1.79. The firm has a market cap of $42.76 million, a P/E ratio of -0.97 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.06). As a group, research analysts expect that Context Therapeutics will post -0.4 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.